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Abstract: Prostate cancer is the most common noncutaneous cancer and the second leading cause of
cancer deaths among American men. Statins and omega-3 are two medications recently found to
correlate with prostate cancer risk and aggressiveness, but the observed associations are complex
and controversial. We therefore explore the novel application of radiomics in studying statin and
omega-3 usage in prostate cancer patients. On MRIs of 91 prostate cancer patients, two regions
of interest (ROIs), the whole prostate and the peripheral region of the prostate, were manually
segmented. From each ROI, 944 radiomic features were extracted after field bias correction and
normalization. Heatmaps were generated to study the radiomic feature patterns against statin or
omega-3 usage. Radiomics models were trained on selected features and evaluated with 500-round
threefold cross-validation for each drug/ROI combination. On the 1500 validation datasets, the
radiomics model achieved average AUCs of 0.70, 0.74, 0.78, and 0.72 for omega-3/prostate, omega-
3/peripheral, statin/prostate, and statin/peripheral, respectively. As the first study to analyze
radiomics in relation to statin and omega-3 uses in prostate cancer patients, our study preliminarily
established the existence of imaging-identifiable tissue-level changes in the prostate and illustrated
the potential usefulness of radiomics for further exploring these medications’ effects and mechanisms
in prostate cancer.
Keywords: radiomics; prostate cancer; statin; omega-3; artificial intelligence; MRI
1. Introduction
Approximately one in seven men in the US will be diagnosed with prostate cancer
in their lives [1]. Prostate cancer is the most prevalent form of noncutaneous cancer and
results in the second-highest number of cancer-related deaths behind only lung cancer.
Since prostate cancer adversely affects so many people, it is essential to study and better
understand the nature of its progression as well as patient prognosis after treatments, with
the ultimate goal of improving treatment plans and their success.
Interesting correlations have been reported between prostate cancer and the use of
statins and omega-3 fatty acids. Statins are a common heart medication, and omega-3 fatty
acids are fish oil supplements. A study in 2018 found that there was a strong correlation
between the use of statins and a reduced risk of prostate cancer metastasis, as well as a
reduced risk of prostate cancer mortality [2]. Another study in 2018 focused on the effects of
omega-3 fatty acids in the diet on prostate cancer tumor progression in mice and concluded
that its use can inhibit the growth and development of tumor cells [3]. However, such
associations have not been consistently observed among different studies, and a causative
association was not fully established nor its mechanism uncovered [4–14]. These intriguing
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associations are complex and controversial, drawing active research for further elucidation.
In this study, we explore the potential utility of radiomics along these efforts in analyzing
the usage of these drugs among a prostate cancer patient population.
Radiomics is a new field of medicine that involves extracting large amounts of quan-
titative data from medical images such as CT scans or MRIs [15,16]. The data extracted
are termed radiomic features, and they can be anything from the intensity of pixels in an
image to the shape and texture of regions of interest (ROIs). These features can also be
extracted from derived images after applying image processing filters. Radiomics therefore
provides additional data that are often not visible to the naked eye. Furthermore, using
modern big data analytics, these large amounts of quantitative data can be studied across
many patients to provide a new dimension of epidemiological data that relates to medical
imaging phenotypes and the underlying biological characteristics.
In prostate cancer, like in many other cancer sites, radiomics has found success in
detecting and diagnosing tumors, characterizing index lesions, predicting tumor aggres-
siveness, evaluating treatment response and prognosis, and associating with tumor ge-
nomics [17–27]. However, to the best of our knowledge, radiomics has never been explored
as a potential tool to investigate the relationship between medication exposure and prostate
cancer. If radiomics signatures can be identified that associate with the use of these drugs,
such radiomics tools can be utilized to further analyze the longitudinal trends between
medication exposure and prostate cancer both during and after cancer development, based
on available medical images. Using radiomics to study the correlation of statins and
omega-3 in prostate cancer management adds a noninvasive, low-cost tool to assess any
potential longitudinal tissue changes related to the drugs. Additionally, the presence of
a defined radiomics signature that could differentiate patients that have been exposed to
these medications and those who have not could help to validate the previous studies
suggesting that these medications do indeed have tissue-level effects on the prostate gland
as a whole as well as in prostate malignancy specifically [28,29]. Therefore, the aim of this
study was to preliminarily explore the utility of radiomics on these novel investigations by
discovering potential feature patterns that could offer further insight into the connections
between prostate cancer and the use of these drugs through the lens of radiomics.
2. Materials and Methods
2.1. Patient Selection and Clinical Data Collection
Male patients who developed prostate cancer and received radiation therapy treat-
ment at our institution between 2007 and 2016 were retrospectively analyzed via electronic
medical records for this study. To be included in the study, patients needed to have a
definitive record of positive or negative use of statins and omega-3 supplements and a
high-resolution T2-weighted MRI scan, at the time of diagnosis. A total of 91 patients met
the criteria and were included in the study. In addition to the diagnostic high-resolution
T2-weighted MRI scan, other information collected for the study included age, ethnicity,
family history, pretreatment PSA, tumor stage, NCCN risk group, and tumor grade. All
data collection was approved by the IRB of our institution (Protocol: 398-17-EP). The charac-
teristics of the studied patient cohort are summarized in Table 1. The percentage of patients
with certain clinical characteristics is also listed in Table 1 for each medication subgroup.
Of the 91 patients, 42 used statins and 28 used omega-3. Among them, 13 patients used
both medications.
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Yes (%) No (%) Yes (%) No (%) N %
Total Number of Patients 42 (46.2%) 49 (53.8%) 28 (30.8%) 63 (69.2%) 91 100%
Age at Diagnosis (median(range)) 66 (54–83)y 67 (54–84)y 65 (57–82)y 68 (54–84)y 67 (54–84)y
Race
White 85.7% 85.7% 82.1% 87.3% 78 85.7%
Non-White 14.3% 14.3% 17.9% 12.7% 13 14.3%
Family History of Prostate Cancer
No 78.6% 75.5% 75.0% 76.2% 70 76.9%
Yes 21.4% 24.5% 25.0% 23.8% 21 23.1%
NCCN Risk Group
Low/Favorable Intermediate 14.3% 14.3% 17.9% 12.7% 13 14.3%
Unfavorable Intermediate 21.4% 18.4% 17.9% 20.6% 18 19.8%
High 21.4% 24.5% 21.5% 23.8% 21 23.1%
Very High 42.9% 42.8% 42.9% 42.9% 39 42.9%
Gleason Grade, Primary
3 (4+3) 40.5% 38.8% 42.9% 38.1% 36 39.6%
4 (8) 54.8% 53.1% 50.0% 55.6% 49 53.8%
5 (9, 10) 4.8% 8.2% 7.1% 6.3% 6 6.6%
Gleason Grade, Secondary
3 (4+3) 23.8% 22.4% 17.9% 25.4% 21 23.1%
4 (8) 23.8% 24.5% 28.6% 22.2% 22 24.2%
5 (9, 10) 52.4% 53.1% 53.6% 52.4% 48 52.8%
cT
cT1c 26.2% 26.5% 21.4% 28.6% 24 26.4%
cT2
cT2a 16.7% 18.4% 21.5% 16.0% 16 17.6%
cT2b 14.3% 8.2% 14.3% 9.5% 10 11.0%
cT2c 7.1% 10.2% 10.7% 7.9% 8 8.8%
cT3 21.4% 22.4% 17.9% 23.8% 20 22.0%
cT3a 14.3% 14.3% 14.3% 14.3% 13 14.3%
cT3b
cN
0 88.1% 85.7% 82.1% 88.9% 79 86.8%
1 11.9% 14.3% 17.9% 11.1% 12 13.2%
PSA







2.2. ROI Contouring and Image Processing
All of the patients received a high-resolution T2-weighted MRI scan in the pelvic
region at diagnosis. The images were taken using Philips Medical Systems Achieva 1.5 T
MRI scanners with a 2 mm slice thickness. Using Velocity software (Varian Medical Systems,
Palo Alto, CA, USA), each MRI scan was manually contoured on two separate ROIs: the
prostate gland and the peripheral zone of the prostate. The whole prostate gland is the
most common region reviewed by radiologists and also easy to contour for future studies,
while the peripheral zone is where over 90% of prostate cancers develop [30]. Figure 1
shows the created contours on two example patients, with the prostate gland outlined in
blue and its peripheral region outlined in red.
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created  to select and analyze specific radiomic  features  that showed a correlation with 
drug usage. The model was trained and tested for its predictability with a workflow, de‐
picted in Figure 2. 
Figure 1. Example contours of the prostate region of interest (ROI) (blue) and the peripheral zone ROI (red).
All of the images and segmented ROIs were then sent to 3D-Slicer v4.10 for image
processing and radiomic feature extraction [31,32]. To avoid bias field distortions and data
heterogeneity bias, a bias field correction using N4 and an image normalization using
histogra matching were performed on all images [33].
. . adio ic eat re tr ti
i i f t -
. [32]. Featur extraction used a resampled voxel size of 2 × 2 × 2 mm3 and a
fixed bin width of 25. A kernel ize f 5 w s used for Laplacian of Gaussian (L G)
feature extraction. F r each ROI, a tot l of 944 adiomic features were extracted. All
of the features re defined in compliance with the feature definitions according to the
Imaging Biomarker Standardization Initiative (IBSI) [34]. They are divided into the origin l
features (107 features), LoG features (93 fe tur s), and wavelet fe t r s (744 features). The
original features contain 14 shape features, 18 first-order statistical features, 14 gray-level
dependence matrix features, 24 gray-level co-occurrence matrix features, 16 gray-level run-
length matrix features, 16 gray-level size zone matrix features, and 5 neighboring gray-tone
difference matrix features. The LoG features are calculated on the derived images applying
a LoG filter. The wavelet features are calculated on the derived i ages by applying either a
high or low pass wavelet filter in each of the three cardinal dimensions, creating a total of 8
different filter combinations (HHH, HHL, HLL, HLH, LLL, LLH, LHL, and LHH). Because
the shape features do not change on the derived images, the LoG and wavelet features do
not include shape features.
2.4. Data Analysis
Heatmaps were first generated based on each ROI to display the radiomic feature
patterns for patients and their correlations with the use of statins or omega-3 supplements.
Four combinations were made: Omega-3/Prostate, Omega-3/Peripheral, Statin/Prostate,
and Statin/Peripheral. For each drug/ROI combination, a machine-learning model was
created to select and analyze specific radiomic features that showed a correlation with drug
usage. The model was trained and tested for its predictability with a workflow, depicted in
Figure 2.





The 4 combinations of drug/ROI were studied  independently  in  the data analysis 
workflow with  the  following steps.  In  the  feature selection step, all patients were  ran‐
domly sampled without replacement for 1000 rounds to use two‐thirds of data for feature 
selection. Using the selected patients in each round, a univariate ANOVA analysis was 














Figure 2. A schematic drawing of the data analysis workflow. Four independent combinations were analyzed, and their
corresponding models were developed to study the effects of each drug on each region of interest (ROI).
The 4 combinations of drug/ROI were studied independently in the data analysis
workflow with the following steps. In the feature selection st p, all pat ents were randomly
sampled withou r placeme t for 1000 rounds to s two-thirds of data for feature s l ction.
Using the selected patients in each round, a univariate ANOVA analysis was first conducted
on all radiomic featur s. Features wi h a false-discovery-rate- djusted value of p < 0.5 were
kept f r the next step. The select d features with Pearson’s correlation coefficient > 0.8
were then group d in clusters, and only the feature with the lowest p-value was kept i
each lus er to furth r reduce the dimension [35]. A sequential floating-forward m thod
was then utilized to select f atures, which gave the highe t area-under-th -curve (AUC)
value with a gradient boost machine-learning model [36]. Only the features that could
improve the AUC by more than 0.01 in each round were kept. All f atures were ranked
by the frequency of those features selected in all 1000 rounds of resampling and the top
10 features were selected.
Model fitting and validation applied a gradient boost machine-learning model [36] using
the default gradient-boosting machine classifier integrated in mlr (v2.18.0) (R Foundation
for Statistical Computing, Vienna, Austria) [37]. The best number of features in a model
was balanced between high bias (an underfitted model) and high variance (an overfitted
model). For each round of model fitting, the total search space is 8 × 4 × 3 × 3 × 3 × 3 = 2596,
including the number of top features from 3 to 10 features (8), the number of trees (4), shrinkage
(3), interaction depth (3), the minimum number of training set samples in a node to commence
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splitting (3), and bag fraction (3). A 500-round randomly sampled 3-fold cross-validation was
applied, yielding 1500 validation tests for each drug/ROI combination. For each test, a receiver
operating characteristic (ROC) analysis was conducted with the AUC and precision-recall
AUC (PRAUC) values calculated. All data analysis was performed using R (version 4.0.2).
3. Results
In the heatmaps shown in Figure 3, the studied patients were clustered into similar
radiomic expression patterns of the prostate gland and the peripheral region of the prostate.
The information regarding statin use and omega-3 use is also included. Two outlier patients
were observed with extreme feature z-scores, but excluding them did not affect feature
selection or model performance (data not shown), likely due to the robust resampling
procedures performed in data analysis.






























Figure 3. Heatmaps showing the radiomics feature pattern across the patient population with the usage of omega-3 and
statin for (A) the prostate ROI and (B) the peripheral ROI.
Follo ing the data analysis pipeline described in the ethods section (Section 2), a
odel was then constructed and tested for each of the four drug/ROI combinations: omega-
3/prostate ROI (six features), omega-3/peripheral ROI (six features), statin/prostate ROI
(six features), and statin/peripheral ROI (six features). On the 150 validation datasets
f t - l t r ef l r ss-validation, the odels ac ieved a r e
( t r deviation) AUCs of 0.70 (± 0.08) for o ega-3/ , . ( . -
peripheral, 0.78 (± 0.07) for statin/prostate, and 0.72 (± 0.09) for stat n/peripheral.
Figure 4 plots the average ROC curves from the validation analyses for these models, and
Figure 5 s ows the validation AUC and PRAUC achieved by each mod l. The selected
radiomic features used in each model are also shown in Figure 5.







Figure 4. Average ROC curves of the radiomics model for ( ) ega-3 usage prediction based on prostate ROI, (B) omega-3
usage prediction based on peri r l ROI, (C) statin usage prediction based on prostate ROI, and (D) statin usage prediction
based on peripheral ROI. The ROC curves are averaged from the 1500 validation test sets.
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el f r ( ) e a-3 sa e re icti ase r state I, ( ) e a-3 sa e re icti ase eri eral I,
(C) statin usage prediction based on prostate ROI, and (D) statin usage prediction based on peripheral ROI. The radiomic
features used in each model are also listed.
4. Discussion
Radiomics is a novel quantitative imagi g approach that involves extracting a large
number of features from medical images and develo ing predictive models based on
high-dimensional data a alysis across large groups of patients. The underlying assumption
is that the modern high-resolution cross-sectional medical images contain information
on biology and physiology that is not fully extracted or utilized by the conventional
qualitative, single-patient approach. Combined with machine learning on populations of
patients to uncover the otherwise hidden information from medical images, radiomics
has been shown to facilitate the detection, diagnosis, and prognosis of many diseases,
especially cancer [15,16,38,39].
Prostate cancer is the most prevalent noncutaneous male cancer and is the second
leading cause of cancer death for men in the United States [1]. Intragland and intratumor
heterogeneity have also been well observed for prostate cancer. Based on MRI used
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in the routine management of prostate cancer, radiomics is well posited to study these
heterogeneities as well as to assess the heterogeneity among different patients. While still
in an early stage of development as a discipline, radiomics has found success in prostate
cancer diagnosis, risk characterization, genomic association, and prognosis prediction,
offering a noninvasive and repeatable approach in these applications [18–22,24,25,27,40].
With recent research, epidemiological, and clinical development in prostate cancer, risk
stratification has become an increasingly central theme in prostate cancer management.
Risk identification and prediction play a critical role in personalized clinician–patient
decision making. Radiomics therefore provides a potential tool for exploring the intricate
interplays between medications and health supplements such as statin and omega-3 and
prostate cancer, which are currently active areas of risk investigations.
In this study, we explored the relationship between radiomics and the use of statins
and omega-3 supplements for a cohort of 91 prostate cancer patients. This study used
radiomic data based on high-resolution T2-weighted MRI, the most used type of medical
imaging technique for prostate cancer diagnosis. On this topic, radiomics is a novel
approach and can be utilized as an effective method to determine possible prostate tissue
effects related to medications with imaging rather than with more invasive/expensive
methods such as biopsies. Two different ROIs were investigated, including the whole
prostate gland and the peripheral region of the prostate. The whole prostate gland is
the most common region reviewed by radiologists, while the peripheral zone is where
over 90% of prostate cancers develop [30], so the two ROIs were separately analyzed
to see if there was a performance difference. Through this study, we identified specific
radiomics signatures that correlated with the use of these drugs and presented machine-
learning models based on these signatures. These signatures were ultimately able to
successfully predict the use of both of these drugs for a given patient with prostate cancer.
Between the two segmented regions, the prostate gland showed a slightly lower AUC
than the peripheral zone (0.70 vs. 0.74) for the omega-3 models but a slightly higher AUC
(0.78 vs. 0.72) for the statin models. On the other hand, the statin/peripheral model used
only three radiomic features, while the other three models used six features. The current
study preliminarily establishes radiomics signatures that help to validate the previously
found tissue-level effect of the medications on the prostate and could allow us to further
investigate the longitudinal tissue effects of statins and omega-3 over the course of prostate
cancer development and growth using this new dimension of data.
There are some limitations to this work. The study was a single-institution, retrospec-
tive study, with a relatively small number of patients (91 patients) meeting the selection
criteria. To maximize the available data and avoid overfitting, we utilized cross-validation
of a large number of random repetitions, and the number of radiomic features in the final
models was also limited to 3–6 features. For omega-3, the data were more unbalanced,
which could also lead to overfitting. To study its effect, we calculated both the AUC
and PRAUC for each model. As expected, bigger drops were observed in the PRAUCs
for the omega-3 models. To further assess the chance of overfitting despite the above
mitigating measures, we also performed a control experiment with a third medication,
angiotensin-converting enzyme inhibitors (ACEI). ACEI is a type of renin–angiotensin
system (RAS) inhibitor and is commonly used to treat hypertension. A few studies have
analyzed the association between ACEI and prostate cancer [41,42]. These studies tend
to suggest that ACEI has no effect on prostate cancer development or progression. In our
cohort, 35 patients (38.5%) reported using ACEIs. Applying our radiomics data analysis
workflow through the ACEI usage data, we achieved an average AUC of 0.58 and an aver-
age PRAUC of 0.49 with the ACEI/prostate model (four features) and 0.54 and 0.52 with
the ACEI/peripheral model (six features). The superior model performances by the statin
and omega-3 models compared with the models of the control medication, ACEI, further
confirmed the validity of our radiomic findings on the two investigated medications.
Additionally, most of the patients in the dataset had their primary care physicians
outside of our institution, so we were unable to have access to the initial lipid profiles
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to assess the reasoning behind their use of these medications or any related medical
care differences that these patients may have. In our study, we individually studied the
four drug/ROI combinations. The medication overlap on the 13 patients that used both
medications was not considered, assuming that the possible mechanisms of prostate cancer
for the two medications are independent of each other. We also did not match the other
patient characteristics for the positive and negative subgroups of each medication. These
choices were made so that the sample size could be maximized for the study. While biases
could possibly be introduced, they are unlikely because there is currently no literature
suggesting a correlation between the mechanisms of the two medications and prostate
cancer, and the patient subgroups are largely balanced on other characteristics, as shown
in Table 1. Furthermore, in this study, we analyzed radiomics based on imaging data
only at a single time point; the time of diagnosis and the effect of varying lengths of
medication usage before this time point were not investigated. While this could have acted
as a confounding factor in this study, the promising findings of this preliminary study
could guide future endeavors to use the radiomics tool for exploring the longitudinal
tissue effects related to these medication uses in the course of prostate cancer development
and progression.
5. Conclusions
For the first time, the potential of radiomics in investigating drug/cancer interactions
was investigated in this study of statin and omega-3 in prostate cancer patients. While
needing further large-scale validations, encouraging findings from this study indicate that
radiomics supports tissue-level effects of these medications and that radiomics can be a
useful tool for future studies on the longitudinal tissue effects related to these medications
in the course of prostate cancer development and progression. Either the whole prostate
gland or the peripheral region could be used as an appropriate volume for future radiomics
studies on this topic.
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